Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Solid Tumors Condition: Intermittent Therapy |
Dose: by mouth – 80 mg/kg Frequency: every 3 days |
|
Indication: Solid Tumors Condition: Continuous Therapy |
Dose: by mouth – 20-30 mg/kg Frequency: once daily |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Sickle-cell disease Age: 1-18 years |
Dose: Oral - 10-20 mg/kg/day Frequency: once daily Note: increased by 5 mg/kg/day every 12 weeks according to response and blood counts; by mouth (oral) |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not specified Note: Dose reduction may be needed. |
Administration
- Take as directed
- Regular timing
Side Effect
- GI disturbances
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Hyperuricemia
- Renal failure
- Rash
- Hyperpigmentation
- Pulmonary oedema
- dermatological reactions
- headache
- dizziness
- Disorientation
- drowsiness
- hallucinations
- convulsions
- alopecia
- Bone marrow suppression
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Vaccines
|
Impairs immune response
|
|
Zidovudine, zalcitabine
|
Possible infection with live vaccines
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Bone-Marrow Suppression
|
Can dangerously reduce blood cells
|
|
Severe Anaemia
|
Can worsen anemia
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.